Vitrolife AB (DE:VTFN)
FRANKFURT:VTFN
VTFN Stock Chart & Stats
€12.08
-€0.26(-1.42%)
At close: 4:00 PM EST
€12.08
-€0.26(-1.42%)
Day’s Range― - ―
52-Week Range€7.76 - €13.70
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€1.12B
Enterprise Value€13.24B
Total Cash (Recent Filing)€886.00M
Total Debt (Recent Filing)€1.58B
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Jul 16, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.01
Shares Outstanding135,447,190
10 Day Avg. Volume3
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio50.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)€321.57M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueVitrolife's core consumables business generates repeat purchases tied to IVF procedure volumes, creating a recurring revenue base. That product stickiness and high usage frequency provide predictable revenue and lower customer churn versus one-time equipment sales, supporting durable cash flow.
Strong Cash Generation (TTM)Despite earnings volatility, Vitrolife produced robust trailing-twelve-month operating cash flow and free cash flow. Persistent positive cash generation enhances financial flexibility for R&D, service expansion, or capex, and reduces near-term refinancing risk versus peers with weaker cash profiles.
Low LeverageThe company's low debt-to-equity indicates limited reliance on external borrowing, lowering financial risk and interest burden. Manageable leverage supports resilience through ART cycle volatility, preserves capacity for strategic investments or acquisitions, and provides runway during weaker revenue periods.
Bears Say
Declining Revenue TrendA sustained decline in revenue reduces operating leverage and undermines growth economics of both consumables and equipment. Lower top-line pressure can compress margins, limit reinvestment into product development and geographic expansion, and indicates potential demand softness in key IVF markets.
Volatile, Negative ProfitabilitySignificant net losses and operating deficits have eroded returns and equity, constraining capital allocation choices. Profit volatility undermines sustainable margin improvement and makes long-term planning and shareholder returns more uncertain, increasing reliance on cash reserves to fund operations.
Cyclicality Of Equipment SalesA meaningful portion of revenue stems from capital equipment that is lumpy and highly correlated with clinic investment cycles. This cyclicality amplifies revenue and margin swings, lengthens recovery after downturns, and makes overall company growth more dependent on external investment trends and regulatory timing.
Vitrolife AB News
VTFN FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was €7.75 and its highest was €13.70 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is €1.12B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Jul 16, 2026 which is in 25 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Apr 23, 2026. The company reported €0.068 earnings per share for the quarter, missing the consensus estimate of €0.071 by -€0.003.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB does not currently pay dividends.
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 0.09.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of €0.068 in its last earnings report, missing expectations of €0.071. Following the earnings report the stock price went down -0.67%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in DE:VTFN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Options Prices
Currently, No data available
---